DaraxonrasibStudy of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Sponsor:

Revolution Medicines, Inc.

Code:

NCT06881784

Conditions

NSCLC (Non-small Cell Lung Cancer)

Non-Small Cell Lung Cancer

NSCLC

NSCLC (Non-small Cell Lung Carcinoma)

NSCLC (Advanced Non-small Cell Lung Cancer)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

daraxonrasib

docetaxel

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-21. This information was provided to ClinicalTrials.gov by Revolution Medicines, Inc. on 2026-08-06.